BCD-178 + trastuzumab + docetaxel + carboplatin

BCD-178 + trastuzumab + docetaxel + carboplatin is an investigational combination therapy under clinical evaluation for the neoadjuvant treatment of HER2-positive breast cancer. BCD-178 is a biosimilar of pertuzumab, a monoclonal antibody targeting the HER2 receptor. Trastuzumab is another HER2-targeting monoclonal antibody, while docetaxel is a taxane-class chemotherapy (antimitotic), and carboplatin is a platinum-based chemotherapy agent that induces DNA cross-linking and apoptosis. This combination aims to exploit dual HER2 blockade and combine cytotoxic chemotherapy to maximize antitumor efficacy in HER2-positive breast cancer patients[3][5][7].